News

In case you missed it, this week we had news about the phase 2/3 research on VDPHL01, new data on the DecisionDx-Melanoma GEP test, roflumilast's sNDA for pediatric plaque psoriasis, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the latest advancements and expert insights from ISDS 2025 held in New York, New York.

Mondana Ghias, MD, FAAD, discusses Tono Health's role in improving access to skin care for patients of color, addressing systemic barriers and enhancing diagnostic accuracy.

Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

Maui Derm NP+PA Fall 2025 conference showcases cutting-edge insights in dermatology, featuring expert discussions on skin cancer, atopic dermatitis, and rare dermatoses.

At Elevate-Derm Fall, Ken Korber, PA-C, MHPE, DFAAPA, highlighted how literacy-aware communication and team-based collaboration can elevate patient understanding, adherence, and outcomes.

Nada Elbuluk, MD, MSc, and Nkem Ugonabo, MD, MPH, discuss safe aesthetic procedures for skin of color, emphasizing tailored techniques and the importance of understanding unique skin biology.

Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.

At Elevate-Derm Fall, Ted Rosen, MD, detailed how rapidly evolving resistance in bacteria, fungi, viruses, and more is reshaping therapeutic choices.

Clinicians can enhance aesthetic outcomes by proactively managing GLP-1 patients' expectations, addressing facial changes early, and integrating holistic treatment strategies.

Dupilumab clears AD clinically and histologically, but deep immune profiling shows disease-memory T cells persist in the skin.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

At Elevate-Derm 2025, Diego Ruiz Dasilva, MD, emphasized cross-role teamwork and urged clinicians to consider positive JAK inhibitor safety data.

Discover how BOTOX Cosmetic Day highlights natural results and patient satisfaction, backed by new research from ASDS on diverse populations and effective treatment strategies.

Stacey Swinehart, DNP, FNP-BC, DCNP, CNL, shares key takeaways for clinicians from the SDNP's recent webinar on detecting intimate partner violence among patients.

Discover the latest insights on hidradenitis suppurativa treatment, emerging therapies, and the importance of compassionate care for patients.

New findings showcase DecisionDx-Melanoma's effectiveness in predicting sentinel lymph node positivity and enhancing recurrence risk assessment in melanoma patients.

Benjamin Ungar, MD, shares groundbreaking insights on seborrheic dermatitis and emerging treatments in dermatology at ISDS 2025.

This review of the latest dermatologic studies highlights new research on acne, including post-treatment recurrence, the use of AI, severity in cystic fibrosis patients, and more.

A recent survey reveals patients prioritize board-certified dermatologists and increasingly favor teledermatology for faster, accessible care.

Veradermics initiates a groundbreaking trial for VDPHL01, an oral minoxidil treatment, addressing female pattern hair loss with innovative solutions.

Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy, according to Michael Lewitt, MD.

Experts discuss hair loss challenges and treatments for skin of color, highlighting the importance of early intervention and accurate diagnosis.

GLP-1 medications are reshaping dermatology, driving increased patient demand for treatments addressing facial volume loss and jowling concerns, according to Joely Kaufman, MD.

Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.

Explore how skin aging and cellular senescence impact overall health, revealing insights into anti-aging strategies and cosmetic conundrums.

AEON Biopharma showcases promising biosimilar data for ABP-450, indicating strong similarity to BOTOX, paving the way for FDA approval.

Kilian Eyerich, MD, PhD, argues that classifying skin diseases by immune response patterns offers clearer therapeutic guidance than traditional morphology.